Ingredient or product comparison
GHK-Cu Animal vs Human Research: Study Design Comparison
Administration Route Subcutaneous or intraperitoneal injection, occasionally topical under occlusion Topical application without occlusion, rare subcutaneous protocols Delivery method accounts for most efficacy variance. IP injection bypasses dermal absorption
This source-based comparison does not add ratings or recommend a winner.
- Administration Route
- Subcutaneous or intraperitoneal injection, occasionally topical under occlusion
- Topical application without occlusion, rare subcutaneous protocols
- Delivery method accounts for most efficacy variance. IP injection bypasses dermal absorption barriers entirely
- Dose Equivalency
- 5–15 mg/kg body weight (350–1,050 mg for 70 kg human equivalent)
- 0.5–2% topical formulations (15–60 mg per application, fractional systemic absorption)
- Direct dose comparison is misleading. Bioavailability differs by 95%+ between routes
- Outcome Measurement
- Histological analysis of tissue samples, direct collagen quantification via hydroxyproline assay
- Non-invasive imaging (ultrasound, profilometry), subjective scales, no biopsy
- Animal data provides mechanistic proof; human data provides clinical relevance. Neither alone is sufficient
- Treatment Duration
- 7–21 days typical, 90 days maximum
- 8–12 weeks standard, no long-term safety data beyond 12 weeks
- Short animal timelines miss chronic effects; short human timelines miss durability of response
- Study Endpoint
- Tissue regeneration, wound closure rate, histopathology
- Skin elasticity, wrinkle depth, hydration, patient-reported outcomes
- Endpoints are fundamentally different. Regeneration vs cosmetic improvement
- Control Methodology
- Saline or copper chloride controls, often with vehicle-matched placebo
- Placebo cream, rarely includes free copper comparison
- Human trials lack the copper-only control needed to isolate peptide-specific effects